by Estrogen blockers work by occupying estrogen receptor sites, thereby preventing natural estrogens from binding to and activating them. They find applications in conditions where excess estrogen activity needs to be inhibited such as breast cancer, endometriosis, and precocious puberty. Estrogen blockers have advantages over other treatment options as they are non-invasive and have mild side effects. The growing incidences of estrogen-related diseases and increasing adoption of plant-based medicines have been driving the demand for estrogen blockers.
The global estrogen blockers market is estimated to be valued at US$ 17.31 Bn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2031.
Key Takeaways
Key players: Key players operating in the estrogen blockers market are Central Drug House, Croda International Plc., Emery Oleochemicals, Glentham Life Sciences Limited, Haihang Industry, Kunshan Odowell Co., Ltd, Matrica S.p.A, OQ Chemicals GmbH, Tokyo Chemical Industry Co., Ltd., and Zhengzhou Yibang Industry & Commerce Co., Ltd.
Growing demand: The increasing incidences of breast cancer, endometriosis, and other estrogen-dominant diseases have been driving the demand for effective treatment options like estrogen blockers. According to WHO, breast cancer is the most common type of cancer in women worldwide.
Global expansion: Leading manufacturers are focusing on expanding their operations in high-growth regions through strategic partnerships and acquisitions. Estrogen Blockers Market Size For instance, in 2019, Zydus Cadila acquired the Belgian pharmaceutical company Complix to strengthen its position in Europe.
Market Key Trends
Increasing use of phytoestrogens: Phytoestrogens or plant-derived estrogens like isoflavones found in soy have gained widespread acceptance as a safer alternative to synthetic estrogen blockers. The ability of phytoestrogens to mimic estrogen action in the body with lesser side-effects is expanding their application scope in healthcare.
Porter’s Analysis:
Threat of new entrants: Low barrier to entry for new companies in the market.
Bargaining power of buyers: High bargaining power for customers as there are many options available from key players.
Bargaining power of suppliers: Suppliers have moderate bargaining power as key players have control over raw material suppliers
Threat of new substitutes: Threat of substitutes is moderate as there are limited options available for estrogen blockers.
Competitive rivalry: High competition among existing key players to maintain market share and position.
Geographical Regions:
North America dominates the estrogen blockers market currently and holds around 40% of the total market share in terms of value. This is attributed to the rising prevalence of breast cancer in countries like the US and Canada. Easy availability of advanced treatment options and large healthcare spending also contribute to the higher adoption.
The Asia Pacific region is expected to witness the fastest growth during the forecast period. This is due to improving healthcare infrastructure, increasing awareness about estrogen-related diseases, and rising disposable income in developing countries such as China and India. Growing medical tourism industry and reduction in treatment costs offer lucrative opportunities for manufacturers in this region.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
